

Index to Volume 10

The index to Volume 10 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *Clinical*

Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January	1-80
February	81-160
March	161-246
April	247-318
May	319-404
June	405-482

Issue	Pages
July	483-566
August	567-650
September	651-730
October	731-806
November	807-890
December	891-990

Subject Index

A

Absorption

glyburide; effects, age, 532
triazolam; interactions, ranitidine, 539

Acetaminophen

osteoarthritis; therapy, geriatrics, ulcer history, 740
pain; therapy, codeine allergies, 658
poisoning; overdose, acetylcysteine therapy, 765
N-Acetylmidoquinone; epilepsy; therapy, review, 335
Acetimidolquinone; metabolites; acetaminophen, toxicity, 765

Acetylcholinesterase inhibitors; Alzheimer's disease; therapy, mechanism of action, review, 447

Acetylcysteine; therapy; acetaminophen overdose, 765
N-Acetylmidoquinone, see Acetimidolquinone

N-Acetyl-D,L-penicillamine; antidotes; mercury poisoning, pediatrics, 213

Achlorhydria; glutamic acid hydrochloride; effects, gastric pH, 866

Acinetobacter species; resistance; ceftazidime, pneumonia, 49

Acquired immunodeficiency syndrome

aminoglycosides; pharmacokinetics, 784
pentamidine; toxicity, pancreatitis, hemophilia, 56
therapy; *Mycobacterium avium* complex, review, 280;
research, AIDS conference, 809

Acyclovir; herpes zoster; and chickenpox, therapy, HIV infections, 301

Acyclovir sodium; herpes zoster; and chickenpox, therapy, HIV infections, 301

Adrenergic agents, see Sympathomimetic agents

Adsorbents; charcoal activated; therapy, impaired phenytoin metabolism, liver diseases, 711

Adverse drug reactions report form, 71, 151, 233, 311, 395, 479, 555, 641, 727, 801, 881, 959

Adverse reactions, see Drugs, adverse reactions

Advertising Index, 80, 160, 246, 318, 404, 482, 558, 650, 730, 806, 890, 976

Age; geriatrics; glyburide pharmacokinetics, 532

AIDS, see Acquired immunodeficiency syndrome

Albumin human; nutrition; parenteral, supplements, dosage predictions, pediatrics, 704

Alcohols, cetyl; combination, colfosceril palmitate, tyloxapal; vs. beractant, therapeutic equivalency, 909

Alfentanil; pharmacology; clinical uses, review, 581

Alfentanil hydrochloride; use; review, criteria, quality assurance programs, 635

Alglucerase; marketing; FDA approvals, 496

Allergies

codeine; alternative analgesics, 658
late; adverse reactions, FDA recommendations, 417

Alteplase; comparison, anistreplase, streptokinase; myocardial infarction therapy, 486

Alzheimer's disease; therapy; mechanism of action, review, 447

Ambulatory care; hypertension; monitoring, devices, assessment, 175

Amikacin

Mycobacterium avium complex; therapy, AIDS, review, 280

resistance; gram-negative bacteria, in vitro, 544

Amino acids; Alzheimer's disease; therapy, mechanism of action, review, 447

Aminoglycosides

amikacin; *Mycobacterium avium* complex, AIDS, 280;
resistance, gram-negative bacteria, in vitro, 544

gentamicin; dosage predictions, pharmacokinetics, methodology, 706; renal function estimation, 931;
pharmacokinetics; AIDS, 784

Anabolic agents; steroids; reclassification, controlled substances, 417

Anabolic Steroids Act of 1990; laws; reclassification, controlled substances, 417

Analgesics and antipyretics

acetaminophen; osteoarthritis therapy, geriatrics, ulcer history, 740; overdose, acetylcysteine therapy, 765

alfentanil hydrochloride; DUE criteria, quality assurance programs, 635; review, 581

codeine; allergies, alternative therapies, 658

fentanyl; FDA approvals, transdermal patches, pain therapy, 9; review, 581

fentanyl citrate; DUE criteria, quality assurance programs, 635

ketorolac tromethamine; DUE criteria, 715

pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667

sufentanil; review, 581

sufentanil citrate; DUE criteria, quality assurance programs, 635

therapy; alternatives, codeine allergies, 658

Androgens; danazol; endometriosis therapy, 518

Anemia; epoetin; therapy, kidney failure, DUE criteria, 143, 303

Anesthetics, local

pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667

Angina pectoris; cardiac drugs; unstable, therapy, 825

Angiotensin-converting enzyme inhibitors

heart failure; congestive, therapy, diastolic dysfunction, 850

kidney diseases; therapy, 25

Anistreplase; comparison, alteplase, streptokinase; myocardial infarction therapy, 486

Antacids; use; evaluation, stress ulcer prophylaxis, criteria, 787

Antianemia drugs; epoetin; DUE criteria, quality assurance programs, 143, 303

Antiarrhythmic drugs, see Cardiac drugs

Antibiotics

Mycobacterium avium complex; therapy, AIDS, review, 280

imipenem; susceptibility, amikacin-resistant isolates, in vitro, 544

vancomycin; dosage guidelines, neonates, 129

vancomycin hydrochloride; blood levels, half-life, hepatic and renal dysfunction, 297

Antibodies; monoclonal; radionuclides, immunotherapy, neoplasms, 359

Anticoagulants

heparin; i.v. infusion sites, toxicity, 630; thromboembolism therapy, guidelines, 503

warfarin; interactions, ciprofloxacin, PT effects, lack, 136; nomograms, dosage, predictions, vs. computers, 923; thromboembolism therapy, guidelines, 503

Anticonvulsants

epilepsy; therapy, review, 335

phenytoin; blood levels, effects, ultrafiltration and freezing, 132; dosage calculations, black African and Indian children, 928

phenytoin sodium; impaired metabolism, liver diseases, activated charcoal therapy, 711

valproate sodium; syrups, availability, vs. valproic acid emulsions, 382

valproic acid; emulsions, availability, vs. valproate sodium syrup, 382

Antidepressants; tricyclic; panic disorders therapy, 893

Antidiabetic agents; glyburide; pharmacokinetics, effects, age, 532

Antidotes

acetylcysteine; acetaminophen overdose, 765

digoxin immune Fab; toxicity, digoxin, 823

heavy-metal antagonists; poisoning, pediatrics, 213

Antiemetics

ondansetron hydrochloride; DUE criteria, quality assurance programs, 471; pharmacology, review, 430;

prophylaxis, chemotherapy toxicity, FDA approvals, 249

Antifungals

fluconazole; DUE criteria, quality assurance programs, 222; pharmacology, review, 179

ketonazole; Cushing's syndrome therapy, 12

Anti-infective agents

Mycobacterium avium complex; combined therapy, AIDS, review, 280

pentamidine; toxicity, pancreatitis, AIDS, 56

pentamidine isethionate; infusions, adverse reactions, facial numbness, 257

Anti-inflammatory agents

aspirin; osteoarthritis therapy, geriatrics, ulcer history, 740

etodolac; osteoarthritis therapy, FDA approvals, 416

Index to Volume 10

The index to Volume 10 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *Clinical*

Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January	1-80
February	81-160
March	161-246
April	247-318
May	319-404
June	405-482

Issue	Pages
July	483-566
August	567-650
September	651-730
October	731-806
November	807-890
December	891-990

Subject Index

A

Absorption

glyburide; effects, age, 532
triazolam; interactions, ranitidine, 539

Acetaminophen

osteoarthritis; therapy, geriatrics, ulcer history, 740
pain; therapy, codeine allergies, 658
poisoning; overdose, acetylcysteine therapy, 765
N-Acetylmidoquinone; epilepsy; therapy, review, 335
Acetimidolquinone; metabolites; acetaminophen, toxicity, 765

Acetylcholinesterase inhibitors; Alzheimer's disease; therapy, mechanism of action, review, 447

Acetylcysteine; therapy; acetaminophen overdose, 765
N-Acetylmidoquinone, see Acetimidolquinone

N-Acetyl-D,L-penicillamine; antidotes; mercury poisoning, pediatrics, 213

Achlorhydria; glutamic acid hydrochloride; effects, gastric pH, 866

Acinetobacter species; resistance; ceftazidime, pneumonia, 49

Acquired immunodeficiency syndrome
aminoglycosides; pharmacokinetics, 784

pentamidine; toxicity, pancreatitis, hemophilia, 56
therapy; *Mycobacterium avium* complex, review, 280;
research, AIDS conference, 809

Acyclovir; herpes zoster; and chickenpox, therapy, HIV infections, 301

Acyclovir sodium; herpes zoster; and chickenpox, therapy, HIV infections, 301

Adrenergic agents, see Sympathomimetic agents

Adsorbents; charcoal activated; therapy, impaired phenytoin metabolism, liver diseases, 711

Adverse drug reactions report form, 71, 151, 233, 311, 395, 479, 555, 641, 727, 801, 881, 959

Adverse reactions, see Drugs, adverse reactions

Advertising Index, 80, 160, 246, 318, 404, 482, 558, 650, 730, 806, 890, 976

Age; geriatrics; glyburide pharmacokinetics, 532
AIDS, see Acquired immunodeficiency syndrome

Albumin human; nutrition; parenteral, supplements, dosage predictions, pediatrics, 704

Alcohols, cetyl; combination, colfosceril palmitate, tyloxapal; vs. beractant, therapeutic equivalency, 909

Alfentanil; pharmacology; clinical uses, review, 581

Alfentanil hydrochloride; use; review, criteria, quality assurance programs, 635

Alglucerase; marketing; FDA approvals, 496

Allergies
codeine; alternative analgesics, 658

late; adverse reactions, FDA recommendations, 417

Alteplase; comparison, anistreplase, streptokinase; myocardial infarction therapy, 486

Alzheimer's disease; therapy; mechanism of action, review, 447

Ambulatory care; hypertension; monitoring, devices, assessment, 175

Amikacin
Mycobacterium avium complex; therapy, AIDS, review, 280

resistance; gram-negative bacteria, in vitro, 544

Amino acids; Alzheimer's disease; therapy, mechanism of action, review, 447

Aminoglycosides
amikacin; *Mycobacterium avium* complex, AIDS, 280;

resistance, gram-negative bacteria, in vitro, 544

gentamicin; dosage predictions, pharmacokinetics, methodology, 706; renal function estimation, 931;

pharmacokinetics; AIDS, 784

Anabolic agents; steroids; reclassification, controlled substances, 417

Anabolic Steroids Act of 1990; laws; reclassification, controlled substances, 417

Analgesics and antipyretics
acetaminophen; osteoarthritis therapy, geriatrics, ulcer history, 740; overdose, acetylcysteine therapy, 765

alfentanil hydrochloride; DUE criteria, quality assurance programs, 635; review, 581

codeine; allergies, alternative therapies, 658

fentanyl; FDA approvals, transdermal patches, pain therapy, 9; review, 581

fentanyl citrate; DUE criteria, quality assurance programs, 635

ketorolac tromethamine; DUE criteria, 715

pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667

sufentanil; review, 581

sufentanil citrate; DUE criteria, quality assurance programs, 635

therapy; alternatives, codeine allergies, 658

Androgens; danazol; endometriosis therapy, 518

Anemia; epoetin; therapy, kidney failure, DUE criteria, 143, 303

Anesthetics, local
pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667

Angina pectoris; cardiac drugs; unstable, therapy, 825

Angiotensin-converting enzyme inhibitors
heart failure; congestive, therapy, diastolic dysfunction, 850

kidney diseases; therapy, 25

Anistreplase; comparison, alteplase, streptokinase; myocardial infarction therapy, 486

Antacids; use; evaluation, stress ulcer prophylaxis, criteria, 787

Antianemia drugs; epoetin; DUE criteria, quality assurance programs, 143, 303

Antiarrhythmic drugs, see Cardiac drugs

Antibiotics

Mycobacterium avium complex; therapy, AIDS, review, 280

imipenem; susceptibility, amikacin-resistant isolates, in vitro, 544

vancomycin; dosage guidelines, neonates, 129

vancomycin hydrochloride; blood levels, half-life, hepatic and renal dysfunction, 297

Antibodies; monoclonal; radionuclides, immunotherapy, neoplasms, 359

Anticoagulants
heparin; i.v. infusion sites, toxicity, 630; thromboembolism therapy, guidelines, 503

warfarin; interactions, ciprofloxacin, PT effects, lack, 136; nomograms, dosage, predictions, vs. computers, 923; thromboembolism therapy, guidelines, 503

Anticonvulsants
epilepsy; therapy, review, 335

phenytoin; blood levels, effects, ultrafiltration and freezing, 132; dosage calculations, black African and Indian children, 928

phenytoin sodium; impaired metabolism, liver diseases, activated charcoal therapy, 711

valproate sodium; syrups, availability, vs. valproic acid emulsions, 382

valproic acid; emulsions, availability, vs. valproate sodium syrup, 382

Antidepressants; tricyclic; panic disorders therapy, 893

Antidiabetic agents; glyburide; pharmacokinetics, effects, age, 532

Antidotes
acetylcysteine; acetaminophen overdose, 765

digoxin immune Fab; toxicity, digoxin, 823

heavy-metal antagonists; poisoning, pediatrics, 213

Antiemetics
ondansetron hydrochloride; DUE criteria, quality assurance programs, 471; pharmacology, review, 430;

prophylaxis, chemotherapy toxicity, FDA approvals, 249

Antifungals
fluconazole; DUE criteria, quality assurance programs, 222; pharmacology, review, 179

ketonazole; Cushing's syndrome therapy, 12

Anti-infective agents
Mycobacterium avium complex; combined therapy, AIDS, review, 280

pentamidine; toxicity, pancreatitis, AIDS, 56

pentamidine isethionate; infusions, adverse reactions, facial numbness, 257

Anti-inflammatory agents
aspirin; osteoarthritis therapy, geriatrics, ulcer history, 740

etodolac; osteoarthritis therapy, FDA approvals, 416

- ibuprofen; interactions, misoprostol, ranitidine, lack, 870; osteoarthritis therapy, geriatrics, ulcer history, 740
 nonsteroidal; pain therapy, codeine allergies, 658
 salsalate; osteoarthritis therapy, geriatrics, ulcer history, 740
 scleroderma; systemic, therapy, 14
- Antilipemic agents**
 cholestyramine resin; palatability, oral formulations, vehicles, 138
 colestipol hydrochloride; palatability, oral formulations, vehicles, 138
 hyperlipidemia; therapy, protocols, 943
- Antimanic agents**
 lithium; neutropenia therapy, HIV infections, review, 268
 lithium carbonate; pharmacokinetics, methodology, models, 376
- Antineoplastic agents**
 fludarabine phosphate; FDA approvals, 496
 fluorouracil and levamisole; colonic neoplasms, combined therapy, 95
 interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141; therapy, review, 110
 levamisole; colorectal neoplasms therapy, review, 95
 toxicity; nausea and vomiting, ondansetron prophylaxis, DUE criteria, 471; neutropenia, filgrastim prophylaxis, DUE criteria, 950; neutropenia, filgrastim prophylaxis, FDA approvals, 321; ondansetron prophylaxis, FDA approvals, 249
- Antithyroid drugs; propylthiouracil; hyperthyroidism therapy, mercury poisoning, 742**
- Antivirals**
 acyclovir; chickenpox, herpes zoster therapy, HIV infections, 301
 zidovudine; toxicity, neutropenia, HIV infections, review, 268
- Anxiolytics, sedatives and hypnotics**
 chloral hydrate; interactions, furosemide, pediatrics, 385
 lorazepam; dosage, pediatrics, 625
 midazolam hydrochloride; DUE criteria, quality assurance programs, 388
 triazolam; interactions, ranitidine, pharmacokinetics, 539
- Arecoline; Alzheimer's disease; therapy, mechanism of action, review, 447**
- Arrhythmia**
 antiarrhythmic agents; therapy, blood levels, monitoring, 211
 cardiac drugs; ventricular, therapy, review, 195
 encainide hydrochloride; toxicity, product withdrawal, 897
 moricizine; therapy, DUE criteria, 873
 therapy; ventricular, pharmacists, monitoring, 210
- Asians; psychotherapeutic agents; pharmacokinetics, vs. Caucasians, 467**
- Aspirin**
 alone and with flurbiprofen; effects, platelet aggregation, 935
 and propoxyphene; pain therapy, codeine allergies, 658
 and thrombolytic agents; myocardial infarction therapy, 486
 myocardial infarction; prophylaxis, angina pectoris, 825
 osteoarthritis; therapy, geriatrics, ulcer history, 740
- Asthma; therapy; pediatrics, 685**
- Availability, drugs, see Drugs, availability**
- B**
- Barbiturates; delirium; therapy, intensive-care units, 456**
- Benazepril hydrochloride; marketing; FDA approvals, 739**
- Benzodiazepines**
 alone and with haloperidol; delirium therapy, intensive-care units, 456
 epilepsy; therapy, review, 335
 panic disorders; therapy, 893
 pharmacokinetics; Asians vs. Caucasians, 467
- Beractant; comparison, alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; therapeutic equivalency, 909**
- Beverages; vehicles; cholestyramine, colestipol administration, palatability, 138**
- Bioavailability, see Drugs, availability**
- Blood derivatives; albumin human; dosage predictions, parental supplements, pediatrics, 704**
- Blood levels**
 acetaminophen; overdose, monitoring, 765
 albumin human; dosage predictions, pediatrics, 704
 antiarrhythmic agents; therapy, monitoring, 211
 benzodiazepines; Asians vs. Caucasians, 467
 cardiac drugs; ventricular arrhythmia therapy, 195
 digoxin; toxicity, digoxin immune Fab retreatment, immunogenicity, 823
 gentamicin; dosage, predictions, pharmacokinetics, 706
 glyburide; pharmacokinetics, effects, age, 532
 lead; succimer therapy, FDA restrictions, 942
 lithium; pharmacokinetics, methodology, models, 376
 mercury; poisoning, pediatrics, 213
 phenytoin; dosage calculations, black African and Indian children, 928; effects, ultrafiltration and freezing, 132; high, impaired metabolism, 711
 reccainam hydrochloride; pharmacokinetics, computer programs, MS-DOS vs. Macintosh, 206
 triazolam; interactions, ranitidine, 539
 valproic acid; availability, stability, emulsions, 382
 vancomycin; dosage guidelines, neonates, 129; half-life, hepatic and renal dysfunction, 297
- Bloodletting; hemochromatosis; therapy, 775**
- Book Reviews, 80, 159, 239, 316, 649, 729, 805, 885, 970**
Biopharmaceutics and Clinical Pharmacokinetics, Fourth Edition, 649
Cancer Chemotherapy by Infusion, Second Edition, 239
Clinical Pharmacology of Psychotherapeutic Drugs, Third Edition, 159
Diseases of the Nose, Throat, Ear, Head, and Neck, Fourteenth Edition, 729
Drug Interactions & Updates, 1991, 805
Drug Safety in Pregnancy, 650
Drugs in Pregnancy and Lactation, Third Edition, 316
Field Drug Reference for Emergency Care Providers, 80
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, 317
Handbook of Drug Therapy in Liver and Kidney Disease, 885
Handbook of Psychiatric Emergencies, 730
Infections in Intravenous Drug Abusers, 805
Manual of Clinical Microbiology, Fifth Edition, 885
Patient Compliance in Medical Practice and Clinical Trials, 970
Pharmacological Treatment of Endocrinopathies: Bone Disease, Kidney Stones and Related Disorders, 890
Poisoning and Drug Overdose, 243
Regional Antineoplastic Drug Delivery in the Management of Malignant Disease, 976
- Books Received, 246, 318, 482, 650, 806, 890, 976**
- Botulinum toxin type A; dystonia; therapy, 88**
- Bristol Laboratories; encainide hydrochloride; product withdrawal, toxicity, 897**
- Bromocriptine; restless legs; therapy, nocturnal, 427**
- Bronchodilators; cromolyn sodium; asthma therapy, pediatrics, 685**
- C**
- Calcium antagonists**
 concomitant therapy, 630
 heart failure; congestive, therapy, diastolic dysfunction, 850
 proteinuria; therapy, diabetic nephropathies, 862
- Calcium regulators; gallium nitrate; hypercalcemia therapy, FDA approvals, 573**
- Calculations; phenytoin; dosage, black African and Indian children, 928**
- Cancer, see Antineoplastic agents**
- Cancer drugs, see Antineoplastic agents**
- Candidiasis; fluconazole; therapy, DUE criteria, 222**
- Captopril**
 concomitant therapy, 500
 kidney diseases; therapy, 25
- Carbamazepine**
 epilepsy; therapy, review, 335
 restless legs; therapy, nocturnal, 427
- Carcinoma; interleukin 2; renal cell, single agent therapy, FDA denial, 141; renal cell, therapy, 110**
- Cardiac drugs**
 angina pectoris; unstable, therapy, 825
 antiarrhythmic agents; therapy, blood levels, monitoring, 211; therapy, monitoring, pharmacists, 210
 arrhythmia; ventricular, therapy, review, 195
 digoxin; toxicity, digoxin immune Fab retreatment, immunogenicity, 823
 encainide hydrochloride; product withdrawal, toxicity, 897
 moricizine; arrhythmia therapy, DUE criteria, 873
 reccainam hydrochloride; pharmacokinetics, computer programs, MS-DOS vs. Macintosh, 206
- Carisoprodol; muscle cramp; therapy, nocturnal leg cramps, 427**
- Caucasians; psychotherapeutic agents; pharmacokinetics, vs. Asians, 467**
- Ceftazidime**
 comparison, ciprofloxacin lactate; therapy, nosocomial pneumonia and urinary tract infections, 49
 effects; amikacin-resistant isolates, in vitro, 544
- Cephalosporins; ceftazidime; susceptibility, amikacin-resistant isolates, in vitro, 544; vs. ciprofloxacin, pneumonia and urinary tract infections therapy, 49**
- Charcoal activated; therapy; impaired phenytoin excretion, liver diseases, 711**
- Chickenpox; acyclovir; therapy, prophylaxis, HIV infections, 301**
- Chloral hydrate; interactions; furosemide, pediatrics, 385**
- Cholestyramine, see Cholestyramine resin**
- Cholestyramine resin**
 hyperlipidemia; therapy, protocols, 943
 palatability; oral formulations, vehicles, preferences, 138
- Choline; Alzheimer's disease; therapy, mechanism of action, review, 447**
- Ciprofloxacin; effects; amikacin-resistant isolates, in vitro, 544**
- Ciprofloxacin hydrochloride; interactions; warfarin, PT effects, lack, 136**
- Ciprofloxacin lactate; comparison, ceftazidime; therapy, nosocomial pneumonia and urinary tract infections, 49**
- Classification; steroids; anabolic, controlled substances, 417**
- Clearance, see Excretion**
- Clindamycin phosphate; concomitant therapy, 931**
- Clinical Pharmacy**
 acknowledgment to reviewers—October 1, 1990, to September 30, 1991, 946
 instructions for submitting computer disks with revised manuscripts, 62
 procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 60
- Clinical studies**
 meta-analysis; health data, applications and problems, 4
 ondansetron hydrochloride; prophylaxis, antineoplastic toxicity, 430
- Codeine; allergies; alternative analgesics, 658**
- Colestipol; hyperlipidemia; therapy, protocols, 943**
- Colestipol hydrochloride; palatability; oral formulations, vehicles, preferences, 138**
- Colfosceril palmitate; combination, alcohols, cetyl, tyloxapol; vs. beractant, therapeutic equivalency, 909**
- Colonic neoplasms**
 fluorouracil and levamisole; combined therapy, review, 95
 levamisole and fluorouracil; combined therapy, review, 95
- Colony-stimulating factors**
 filgrastim; DUE criteria, 950
 neutropenia; therapy, HIV infections, review, 268
 sargamostim; DUE criteria, 947
- Colorectal neoplasms**
 interleukin 2; therapy, 110
 levamisole; therapy, review, 95
- Combined therapy**
 aspirin and thrombolytic agents; myocardial infarction, effects, mortality, 486
 fluorouracil and levamisole; colonic neoplasms, review, 95
 levamisole and fluorouracil; colonic neoplasms, review, 95
 thrombolytic agents and aspirin; myocardial infarction, effects, mortality, 486
- Commentary, 943**
- Compliance; patients; deferaxamine therapy, hemochromatosis, 775**
- Computers; programs; MS-DOS vs. Macintosh, reccainam pharmacokinetics, 206; NONMEM, lithium pharmacokinetics, 376; warfarin dosage, predictions, vs. nomogram, 923**
- Contraceptives, oral; endometriosis; therapy, 518**
- Contraindications**
 botulinum toxin type A, 88
 drugs; lactation, 594
- Controlled substances; steroids; anabolic, reclassification, 417**
- Copper Cu 67; radionuclides; monoclonal antibodies, neoplasms, 359**
- Correction Notices, 261, 429, 501, 824, 913**
 Attention-deficit hyperactivity disorder (Aug 1990, Therapy Review), 261
 Criteria for use of ketorolac tromethamine in adult

- inpatients and outpatients (Sep 1991, DUE Criteria), 913
- Current issues in the treatment of epilepsy (May 1991, Therapy Review), 501
- Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin (Feb 1991, Research Notes), 429
- Intravenous quinidine recommended for severe *Plasmodium falciparum* malaria; injectable quinidine discontinued by CDC Drug Service (Sep 1991, News), 913
- Management of postoperative pain by continuous epidural infusion of analgesics (Oct 1991, Therapy Review), 824
- Olsalazine approved for use in ulcerative colitis (Dec 1990, News), 261
- Costs**
- deferoxamine mesylate; hemochromatosis therapy, 775
- filgrastim; prophylaxis, neutropenia, FDA approvals, 321
- interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141
- pulmonary surfactants; respiratory distress syndrome therapy, 909
- sargramostim, 411
- thrombolytic agents; myocardial infarction therapy, 486
- CP Continuing Education**, 68, 147, 228, 309, 392, 474, 552, 638, 718, 792, 876, 953
- Creatinine**; clearance; gentamicin excretion, renal function estimation, 931; predictions, lithium pharmacokinetics, models, 376
- Cromolyn sodium**; asthma; therapy, pediatrics, 685
- Current Literature**, 74, 154, 235, 313, 397, 478, 558, 644, 726, 803, 880, 966
- Cushing's syndrome**; ketoconazole; therapy, mechanism of action, 12
- Cytokines**; *Mycobacterium avium* complex; therapy, AIDS, review, 280
- Cytotoxic agents**, see **Antineoplastic agents**
- D**
- Danazol**; endometriosis; therapy, 518
- Deferoxamine mesylate**; hemochromatosis; therapy, 775
- Delirium**; therapy; review, intensive-care units, 456
- Desmopressin acetate**; dosage; high, mechanism of action, antidiuretic effects, 912
- Devices**
- blood pressure; ambulatory care, monitoring, assessment, 175
- infusion pumps; terbutaline, preterm labor, home therapy, 292
- medical; latex, adverse reactions, FDA recommendations, 417
- Diabetes mellitus**; calcium antagonists; diabetic nephropathies, proteinuria therapy, 862
- Diabetic nephropathies**; calcium antagonists; proteinuria therapy, diabetes mellitus, 862
- Digoxin**; toxicity; therapy, digoxin immune Fab retreatment, immunogenicity, 823
- Digoxin immune Fab**; therapy; immunogenicity, retreatment, 823
- Diltiazem**
- angina pectoris; unstable, therapy, 825
- proteinuria; therapy, diabetic nephropathies, 862
- Dimercaprol**; antidotes; mercury poisoning, pediatrics, 213
- Diuretics**
- and doxazosin mesylate; hypertension therapy, 9
- furosemide; interactions, chloral hydrate, pediatrics, 385
- heart failure; congestive, therapy, diastolic dysfunction, 850
- Dosage**
- acyclovir; chickenpox, herpes zoster therapy, HIV infections, 301
- albumin human; predictions, equations, parenteral supplements, pediatrics, 704
- alfentanil hydrochloride; DUE criteria, 635
- analgesics; pain therapy, pediatrics, 667
- benazepril hydrochloride, 739
- charcoal activated; multiple dose therapy, phenytoin toxicity, liver diseases, 711
- desmopressin acetate; high, mechanism of action, antidiuretic effects, 912
- digoxin immune Fab, 823
- doxazosin mesylate; hypertension, therapy, 9
- enalapril maleate; DUE criteria, 63
- epoetin; DUE criteria, 143, 303
- etodolac, 416
- fentanyl; transdermal patches, pain therapy, 9
- fentanyl citrate; DUE criteria, 635
- filgrastim, 321; neutropenia prophylaxis, chemotherapy, DUE criteria, 950
- fluconazole; DUE criteria, 222
- fludarabine phosphate, 496
- gallium nitrate, 573
- gastrointestinal drugs; stress ulcer prophylaxis, DUE criteria, 787
- gentamicin; predictions, pharmacokinetics, methodology, 706
- heparin; thromboembolism therapy, guidelines, 503
- hetastarch; DUE criteria, 549
- interleukin 2; neoplasms therapy, 110
- isradipine, 573
- ketorolac tromethamine; DUE criteria, 715
- levamisole; colorectal neoplasms therapy, 95
- lorazepam; sedation, amnesia, pediatrics, 625
- midazolam hydrochloride; DUE criteria, 388
- misoprostol; DUE criteria, 307
- morizine; arrhythmia therapy, DUE criteria, 873
- ondansetron hydrochloride, 249; DUE criteria, 471; review, 430
- overdose; acetaminophen, acetylcysteine therapy, 765
- phenytoin; calculations, black African and Indian children, 928
- psychotherapeutic agents; Asians vs. Caucasians, 467
- pulmonary surfactants; respiratory distress syndrome therapy, 909
- radiopharmaceuticals; monoclonal antibodies, neoplasms, 359
- ramipril, 573
- sargramostim, 411; DUE criteria, 947
- skeletal muscle relaxants; mechanically ventilated patients, 32
- succimer; lead poisoning, therapy, 914
- sufentanil citrate; DUE criteria, 635
- terbutaline sulfate; preterm labor, home infusion therapy, 292
- vancomycin; guidelines, neonates, 129
- vancomycin hydrochloride; hepatic and renal dysfunction, 297
- warfarin; predictions, nomograms vs. computers, 923; thromboembolism therapy, guidelines, 503
- Dosage forms**
- etodolac, 416
- filgrastim, 321
- ondansetron hydrochloride, 249
- sargramostim, 411
- Dosage schedules**
- acetylcysteine; therapy, acetaminophen overdose, 765
- analgesics; continuous epidural infusions, postoperative pain, 745
- anticonvulsants; epilepsy therapy, long term, 335
- aspirin and flurbiprofen; platelet aggregation effects, 935
- flurbiprofen and aspirin; platelet aggregation effects, 935
- interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141
- Doxazosin mesylate**; hypertension; therapy, FDA approvals, 9
- Drug administration**
- cholestyramine resin; beverages, palatability, 138
- colestipol hydrochloride; beverages, palatability, 138
- self-medication; terbutaline infusion, preterm labor therapy, 292
- succimer; lead poisoning, therapy, 914
- thrombolytic agents; comparisons, myocardial infarction therapy, 486
- Drug administration rate**; injections; continuous vs. intermittent infusion, toxicity, 630
- Drug administration routes**
- asthma; acute vs. prophylactic therapy, pediatrics, 685
- deferoxamine mesylate; s.c., i.v., hemochromatosis therapy, 775
- epidural; analgesics, continuous epidural infusions, postoperative pain, 745
- pentamidine isethionate; infusions, adverse reactions, facial numbness, 257
- terbutaline sulfate; subcutaneous infusion, preterm labor therapy, 292
- triazolam; oral vs. i.v., interactions, ranitidine, pharmacokinetics, 539
- Drug administration sites**; intravenous; toxicity, extravasation, phlebitis, 630
- Drug interactions**
- chloral hydrate and furosemide; pediatrics, 385
- ciprofloxacin hydrochloride and warfarin; PT effects, lack, 136
- fluconazole; review, 179
- flurbiprofen and aspirin; effects, platelet aggregation, lack, 935
- furosemide and chloral hydrate; pediatrics, 385
- ibuprofen and misoprostol or ranitidine hydrochloride; lack, 870
- misoprostol and ibuprofen; lack, 870
- ranitidine hydrochloride and ibuprofen; lack, 870
- ranitidine hydrochloride and triazolam; pharmacokinetics, 539
- triazolam and ranitidine hydrochloride; pharmacokinetics, 539
- warfarin and ciprofloxacin hydrochloride; PT effects, lack, 136
- Drug interactions therapy**; aspirin and flurbiprofen; effects, platelet aggregation, lack, 935
- Drug Reaction Alerts**, 74, 154, 235, 313, 397, 478, 558, 644, 726, 803, 880, 966
- Drugs, adverse reactions**
- codeine; allergies, alternative analgesics, 658
- latex; allergies, FDA recommendations, 417
- pentamidine isethionate; facial numbness, infusions, 257
- vaccines; Vaccine Adverse Event Reporting System, 9
- Drugs, availability**
- triazolam; interactions, ranitidine, 539
- valproate sodium; syrups, vs. valproic acid emulsions, 382
- valproic acid; emulsions, vs. valproate sodium syrup, 382
- Drugs, body distribution**
- aminoglycosides; AIDS, 784
- glyburide; effects, age, 532
- lithium; pharmacokinetics, methodology, models, 376
- Drugs, clinical effectiveness**
- antiarrhythmic agents; therapy, blood levels, monitoring, 211
- drugs, nonprescription; lack, product withdrawal, FDA list, 88
- meta-analysis; methodology, applications and problems, 4
- thrombolytic agents; myocardial infarction therapy, 486
- Drugs, nonprescription**; product withdrawal; ingredients, FDA list, 88
- Drug use**
- evaluation; filgrastim, neutropenia prophylaxis, criteria, 950; gastrointestinal drugs, stress ulcer prophylaxis, criteria, 787; ketorolac, criteria, 715; morizine, arrhythmia therapy, criteria, 873; sargramostim, criteria, 947
- review; alfentanil, fentanyl, sufentanil, criteria, quality assurance programs, 635; enalapril, criteria, quality assurance programs, 63; epoetin, criteria, quality assurance programs, 143, 303; fluconazole, criteria, quality assurance programs, 222; hetastarch, criteria, quality assurance programs, 549; midazolam, criteria, quality assurance programs, 388; misoprostol, criteria, quality assurance programs, 307; ondansetron, criteria, quality assurance programs, 471
- DUE Criteria**, 63, 143, 222, 303, 388, 471, 549, 635, 715, 787, 873, 947
- enalapril maleate, 63
- epoetin, 143, 303
- fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride, 635
- filgrastim, 950
- fluconazole, 222
- hetastarch, 549
- ketorolac tromethamine, 715
- midazolam hydrochloride, 388
- misoprostol, 307
- morizine, 873
- ondansetron hydrochloride, 471
- sargramostim, 947
- stress ulcer prophylaxis in intensive-care patients, 787
- Dystonia**; botulinum toxin type A; therapy, 88
- E**
- Edetate calcium disodium**; therapy; mercury poisoning, 742
- Editorials**, 141, 210, 942
- Antiarrhythmic monitoring: misplaced emphasis, 211
- Recombinant interleukin-2 and the quest for FDA approval, 141
- Succimer: controversial issues involving the release of a new product, 942
- Trials and tribulations of evaluating ventricular arrhythmias, 210
- Education**
- acquired immunodeficiency syndrome; therapy, re-

search, AIDS conference, 809
 panic disorders; awareness, therapy, 893
Elimination, see **Metabolism**
Emulsions; valproic acid; stability, availability, vs. valproate sodium syrup, 382
Enalapril maleate
 kidney diseases; therapy, 25
 use; review, criteria, quality assurance programs, 63
Enalapril maleate; product withdrawal; toxicity, 897
Endometriosis; therapy, 518
Enterobacter cloacae; resistance; ceftazidime, pneumonia, 49
Enzymes; alglucerase; replacement therapy, Gaucher's disease, FDA approvals, 496
Epilepsy; therapy; review, 335
Epoetin; use; review, criteria, quality assurance programs, 143, 303
Equations
 albumin human; dosage, predictions, pediatrics, 704
 phenytoin; dosage, pediatrics, pharmacogenetics, 928
Equivalency
 valproate sodium; syrups, availability, vs. valproic acid emulsions, 382
 valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
Equivalency, generic; thioridazine hydrochloride; brands, comparison, efficacy, quality of life, 938
Equivalency, therapeutic; pulmonary surfactants; comparison, respiratory distress syndrome therapy, 909
Ethnic groups; Hispanic Americans; psychotherapeutic agents, pharmacogenetics, 467
Ethosuximide; epilepsy; therapy, review, 335
Etidolac; marketing; FDA approvals, osteoarthritis therapy, 416
Excretion
 aminoglycosides; AIDS, 784
 benzodiazepines; clearance, Asians vs. Caucasians, 467
 drugs; lactation, review, 594
 gentamicin; renal function estimation, 931
 glyburide; effects, age, 532
 lithium; clearance, methodology, models, 376
 phenytoin sodium; impaired, liver diseases, activated charcoal therapy, 711
 vancomycin; hepatic and renal dysfunction, 297
Extravasation; injections; i.v. infusion sites, toxicity, 630

F

Fentanyl
 patches transdermal; pain therapy, FDA approvals, 9
 pharmacology; clinical uses, review, 581
Fentanyl citrate; use; review, criteria, quality assurance programs, 635
Filgrastim
 approvals; FDA, prophylaxis, neutropenia, chemotherapy, 321
 use; evaluation, neutropenia prophylaxis, criteria, 950
Filters; ultra; products, effects, phenytoin blood levels, 132
Filtration; ultra; methods, phenytoin blood levels, 132
Fluconazole
 pharmacology; review, 179
 use; review, criteria, quality assurance programs, 222
Fludarabine phosphate; marketing; FDA approvals, 496
Fluorouracil; and levamisole; colonic neoplasms, combined therapy, 95
Flurbiprofen; alone and with aspirin; effects, platelet aggregation, 935
Food and Drug Administration (U.S.)
 approvals; alglucerase marketing, 496; benazepril marketing, 739; doxazosin, hypertension therapy, 9; etidolac marketing, 416; fentanyl, transdermal patches, marketing, pain therapy, 9; filgrastim marketing, 321; fludarabine marketing, 496; gallium marketing, 573; isradipine, ramipril, marketing, 573; ondansetron, 249; sargramostim marketing, 411; succimer marketing, controversies, 942
 drugs, nonprescription; ingredients, product withdrawal, list, 88
 interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141
 latex; medical devices, allergies, recommendations, 417
Formulations
 cholestyramine resin; oral, palatability, vehicles, 138
 colestipol hydrochloride; oral, palatability, vehicles, 138
Freezing; effects; phenytoin blood levels, ultrafiltration methods, 132

5-FU, see **Fluorouracil**
Furosemide; interactions; chloral hydrate, pediatrics, 385

G

Gallium nitrate; marketing; FDA approvals, 573
Gastrointestinal drugs
 glutamic acid hydrochloride; effects, gastric pH, 866
 histamine H₂ antagonists; use, evaluation, stress ulcer prophylaxis, criteria, 787
 misoprostol; DUE criteria, quality assurance programs, 307; interactions, ibuprofen, lack, 870
 ranitidine; peptic ulcers, prophylaxis, osteoarthritis, geriatrics, 740
 ranitidine hydrochloride; interactions, ibuprofen, lack, 870; interactions, triazolam, pharmacokinetics, 539
 scleroderma; systemic, therapy, 14
 sucralfate; stress ulcer prophylaxis, DUE criteria, 787
Gaucher's disease; alglucerase; therapy, FDA approvals, 496
Gentamicin
 dosage; predictions, pharmacokinetics, methodology, 706
 excretion; renal function estimation, 931
Geriatrics; osteoarthritis; therapy, ulcer history, 740
Globulin immune; neutropenia; therapy, HIV infections, review, 268
Glutamic acid hydrochloride; effects; gastric pH, 866
Glyburide; pharmacokinetics; effects, age, 532
Goserelin agonists; nafarelin; endometriosis therapy, 518
Guidelines, treatment, see **Protocols**

H

Half-life
 aminoglycosides; AIDS, 784
 vancomycin; blood levels, hepatic and renal dysfunction, 297
Haloperidol; alone and with benzodiazepines; delirium therapy, intensive-care units, 456
Health-benefit programs; reimbursement; meta-analysis, 4
Health care; home; terbutaline infusion, preterm labor therapy, 292
Health professions; latex; medical devices, allergies, FDA recommendations, 417
Heavy metal antagonists
 N-acetyl- α -penicillamine; mercury poisoning, pediatrics, 213
 deferoxamine mesylate; hemochromatosis therapy, 775
 dimercaprol; mercury poisoning, pediatrics, 213
 edetate calcium disodium; therapy, mercury poisoning, 742
 penicillamine; hepatolenticular degeneration therapy, 839
 succimer; FDA approvals, controversies, 942; lead poisoning, therapy, 914
 trientine; hepatolenticular degeneration therapy, 839
 zinc; hepatolenticular degeneration, maintenance therapy, 839
Hemochromatosis; therapy, 775
Hemophilia; pentamidine; toxicity, pancreatitis, AIDS, 56
Heparin
 injections; i.v. infusion sites, toxicity, 630
 myocardial infarction; prophylaxis, angina pectoris, 825
 thromboembolism; therapy, guidelines, 503
Hepatolenticular degeneration; heavy metal antagonists; therapy, 839
Herpes zoster; acyclovir; therapy, prophylaxis, HIV infections, 301
Hetastarch; use; review, criteria, quality assurance programs, 549
History; skeletal muscle relaxants; review, developments, 32
HIV infections
 acyclovir; chickenpox, herpes zoster therapy, HIV infections, 301
 therapy; neutropenia, review, 268; research, AIDS conference, 809
Hodgkin's disease; sargramostim; therapy, FDA approvals, 411
Hospitals; intensive-care units; delirium therapy, review, 456; patients, stress ulcer prophylaxis, DUE criteria, 787
Hyperalimentation, see **Nutrition**; **parenteral**

Hypercalcemia; gallium nitrate; therapy, cancer-related, FDA approvals, 573
Hypertlipidemia; therapy; protocols, National Cholesterol Education Program, 943
Hypertension
 benazepril hydrochloride; therapy, FDA approvals, 739
 calcium antagonists; therapy, diabetic nephropathies, 862
 doxazosin mesylate; therapy, FDA approvals, 9
 enalapril maleate; DUE criteria, 63
 isradipine; therapy, FDA approvals, 573
 labetalol hydrochloride; therapy, pediatrics, 500
 ramipril; therapy, FDA approvals, 573
 therapy; ambulatory care, monitoring, assessment, 175
Hyperthyroidism; mercury; toxicity, poisoning, 742
Hypotensive agents
 benazepril hydrochloride; FDA approvals, 739
 doxazosin mesylate; therapy, FDA approvals, 9
 enalapril maleate; DUE criteria, quality assurance programs, 63
 isradipine; FDA approvals, 573
 labetalol hydrochloride; therapy, pediatrics, 500
 ramipril; FDA approvals, 573

I

Iatrogenic diseases, see **Drugs**, **adverse reactions**
Ibuprofen
 interactions; misoprostol, ranitidine, lack, 870
 osteoarthritis; therapy, geriatrics, ulcer history, 740
Imipenem; effects; amikacin-resistant isolates, in vitro, 544
Immunogenicity; digoxin immune Fab; retreatment, digoxin toxicity, 823
Immunosuppressive agents; scleroderma; systemic, therapy, 14
Immunotherapy
 colony-stimulating factors; neutropenia, HIV infections, review, 268
 filgrastim; neutropenia prophylaxis, chemotherapy, DUE criteria, 950; prophylaxis, neutropenia, FDA approvals, 321
 globulin immune; neutropenia, HIV infections, review, 268
 interleukin 2; neoplasms therapy, 110
 radionuclides; monoclonal antibodies, neoplasms, 359
 sargramostim; DUE criteria, 947; FDA approvals, 411
Incompatibilities; ondansetron hydrochloride; review, 430
Infections; therapy; opportunistic, research, AIDS conference, 809
Infusion devices, see **Devices**; **infusion pumps**
Injections
 analgesics; continuous epidural infusions, postoperative pain, 745
 botulinum toxin type A; dystonia therapy, 88
 furosemide; interactions, chloral hydrate, pediatrics, 385
 gallium nitrate; hypercalcemia therapy, FDA approvals, 573
 intravenous; toxicity, extravasation, phlebitis, 630
 pentamidine isethionate; infusions, adverse reactions, facial numbness, 257
 terbutaline sulfate; subcutaneous infusion, preterm labor therapy, 292
Interleukin 2
 approvals; renal cell carcinoma, single agent therapy, FDA denial, 141
 neoplasms; therapy, review, 110
Iodine 1 125; radionuclides; monoclonal antibodies, neoplasms, 359
Iodine 1 131; radionuclides; monoclonal antibodies, neoplasms, 359
Isradipine; marketing; FDA approvals, 573

K

Ketoconazole; Cushing's syndrome; therapy, mechanism of action, 12
Ketorolac tromethamine; use; evaluation, criteria, 715
Kidney diseases; angiotensin-converting-enzyme inhibitors; therapy, 25
Kidney failure; vancomycin hydrochloride; chronic, blood levels, half-life, 297
Klebsiella pneumoniae; resistance; ciprofloxacin, pneumonia, 49

L

- Labetalol hydrochloride**; hypertension; therapy, pediatrics, 500
- Labor**; terbutaline sulfate; preterm, home infusion therapy, 292
- Lactation**; drugs; patient information, excretion, review, 594
- Latex**; adverse reactions; allergies, FDA recommendations, 417
- Laws**; Anabolic Steroids Act of 1990; reclassification, controlled substances, 417
- Lead**; poisoning; succimer therapy, 914; succimer therapy, FDA approvals, controversies, 942
- Lecithin**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Letters**, 177, 257, 333, 429, 500, 664, 742, 823, 912
- Antimicrobial dosages in guidelines for prevention of bacterial endocarditis, 501
- Correction to *AHFS Drug Information* 91, 913
- Cryoprecipitate for uremic bleeding, 429
- Dosage of antimycobacterial agents, 664
- Ethnicity and clozapine-induced agranulocytosis, 743
- Hyperthyroidism associated with mercury poisoning, 742
- Interferon for genital warts, 177
- Inverse relationship between desmopressin dosage and antidiuresis, 912
- Labetalol for treatment of hypertension in a child, 500
- Laboratory monitoring of heparin therapy, 824
- Pentamidine-induced facial numbness, 257
- Retreatment with digoxin immune Fab, 823
- Valproic acid hepatotoxicity in adults and older children, 665
- Verapamil and left ventricular hypertrophy, 333
- Leukemia**
- fludarabine phosphate; B-cell, chronic, therapy, FDA approvals, 496
- sargramostim; lymphocytic, acute, therapy, FDA approvals, 411
- Levamisole**; colorectal neoplasms; therapy, review, 95
- Lisinopril**; kidney diseases; therapy, 25
- Lithium**; neutropenia; therapy, HIV infections, review, 268
- Lithium carbonate**; pharmacokinetics; methodology, models, 376
- Liver cirrhosis**; vancomycin hydrochloride; blood levels, half-life, 297
- Liver diseases**; phenytoin sodium; impaired metabolism, activated charcoal therapy, 711
- Lorazepam**; dosage; sedation, amnesia, pediatrics, 625
- Lymphoma**
- radioculclides; monoclonal antibodies, 359
- sargramostim; non-Hodgkin's, therapy, FDA approvals, 411

M

- Magnesium sulfate**; concomitant therapy, 292
- Manufacturing**; valproic acid; emulsions, availability, fresh vs. stored, 382
- Marketing**
- alglucerase; FDA approvals, 496
- benazepril hydrochloride; FDA approvals, 739
- doxazosin mesylate; hypertension therapy, FDA approvals, 9
- encainide hydrochloride; product withdrawal, toxicity, 897
- etodolac; osteoarthritis therapy, FDA approvals, 416
- fentanyl; transdermal patches, FDA approvals, pain therapy, 9
- filgrastim; prophylaxis, neutropenia, FDA approvals, 321
- fludarabine phosphate; FDA approvals, 496
- gallium nitrate; FDA approvals, 573
- isradipine; FDA approvals, 573
- ondansetron hydrochloride; prophylaxis, chemotherapy toxicity, FDA approvals, 249
- product withdrawal; nonprescription drugs, FDA list, 88
- ramipril; FDA approvals, 573
- sargramostim; FDA approvals, 411
- succimer; FDA approvals, controversies, 942
- Mechanism of action**
- acetylcholinesterase inhibitors; Alzheimer's disease therapy, review, 447
- amino acids; Alzheimer's disease therapy, review, 447
- analgesics; continuous epidural infusions, postoperative pain, 745; pain therapy, pediatrics, 667
- calcium antagonists; proteinuria therapy, diabetic nephropathies, 862
- desmopressin acetate; high dose, antidiuretic effects, 912
- ketoconazole; Cushing's syndrome therapy, 12
- parasympathomimetic agents; Alzheimer's disease therapy, review, 447
- Melanoma**; interleukin 2; therapy, 110
- Memory disorders**; therapy; Alzheimer's disease, review, 447
- Meningitis**; fluconazole; cryptococcal, therapy, DUE criteria, 222
- Mercury**
- poisoning; dimercaprol, N-acetyl-D,L-penicillamine, antidotes, pediatrics, 213; toxicity, hyperthyroidism, 742
- Metabolism**
- acetaminophen; acetaminophen metabolites, toxicity, 765
- phenytoin sodium; impaired, liver diseases, activated charcoal therapy, 711
- Metals**; mercury; poisoning, hyperthyroidism toxicity, 742; poisoning, pediatrics, 213
- Methodology**
- albumin human; dosage predictions, parenteral supplements, pediatrics, 704
- antiarrhythmic agents; therapy, blood levels, monitoring, 211
- cardiac drugs; monitoring, ventricular arrhythmia therapy, 195
- creatinine; clearance, gentamicin excretion, renal function estimation, 931
- gentamicin; dosage predictions, pharmacokinetics, 706
- lithium carbonate; pharmacokinetics, models, 376
- meta-analysis; health data, applications and problems, 4
- pharmacokinetics; computer programs, MS-DOS vs. Macintosh, 206
- phenytoin; dosage, pediatrics, pharmacogenetics, 928
- warfarin; dosage predictions, nomograms vs. computers, 923
- Midazolam hydrochloride**; use; review, criteria, quality assurance programs, 388
- Misoprostol**
- interactions; ibuprofen, lack, 870
- use; review, criteria, quality assurance programs, 307
- Models**; pharmacokinetics; recainam, computer programs, MS-DOS vs. Macintosh, 206
- Monoamine oxidase inhibitors**; panic disorders; therapy, 893
- Moricizine**; use; evaluation, arrhythmia therapy, criteria, 873
- Mortality**; myocardial infarction; effects, thrombolytic agents and aspirin, 486
- Muscle cramp**; therapy; nocturnal leg cramps, 427
- Mycobacterium avium complex**; therapy; AIDS, review, 280
- Myocardial infarction**
- aspirin and thrombolytic agents; comparisons, therapy, 486
- thrombolytic agents; comparisons, therapy, 486

N

- Nafarelin**; endometriosis; therapy, 518
- National Cholesterol Education Program**; protocols; hyperlipidemia therapy, 943
- Nausea**; ondansetron hydrochloride; therapy, DUE criteria, 471
- Negatives**; psychotherapeutic agents; pharmacogenetics, 467
- Neoplasms**
- radioculclides; monoclonal antibodies, 359
- therapy; research, AIDS conference, 809
- Neutropenia**
- filgrastim; prophylaxis, chemotherapy, FDA approvals, 321
- therapy; HIV infections, review, 268
- News**, 4, 88, 167, 249, 321, 411, 486, 569, 653, 733, 809, 893
- American Academy of Pediatrics issues recommendations on treatment of Lyme disease, 738
- Anabolic steroids reclassified as Schedule III controlled substances, 417
- Benazepril approved for treatment of hypertension, 739
- Bristol discontinues sales of encainide, 897
- CAST II halted because of mortality trends, 897
- CDC offers recommendations for follicle acid prevention of neural tube defects, 898
- CDC publishes guidelines for amniocentesis in HIV-infected persons, 653
- CDC revises mefloquine dosage recommendations, 417
- Changes in federal programs for reporting suspected adverse reactions to vaccines announced, 9
- Conference attendees told ISIS-3 shows equal efficacy, safety differences among thrombolytics, 486
- Consensus panel considers uses of botulinum toxin, 88
- Consensus panel stresses need for greater awareness of panic disorder and its treatment, 893
- Consensus report focuses on hypertension during pregnancy, 93
- Doxazosin approved as antihypertensive agent, 9
- ES antitendotoxin antibody reduces mortality among subset of patients with gram-negative sepsis, study finds, 897
- Enzyme replacement therapy approved for Gaucher's disease, 496
- Etodolac approved for marketing in the United States, 416
- FDA advisory committee reviews data suggesting ethnic differences in response to zidovudine, recommends no changes in drug use, 326
- FDA bans 223 ingredients in nonprescription drug products, 88
- Fludarabine approved for marketing, 496
- Gallium marketed for treatment of cancer-related hypercalcemia, 573
- Guidelines for *Pneumocystis carinii* pneumonia prophylaxis in children issued, 569
- Haemophilus b* immunization recommendations updated by American Academy of Pediatrics, 733
- Highlights of the Seventh International Conference on AIDS, 809
- Intravenous quinidine recommended for severe *Plasmodium falciparum* malaria; injectable quinidine discontinued by CDC Drug Service, 653
- Latex in medical devices may cause severe reactions; extra care advised, 417
- Marketing of recombinant granulocyte-macrophage colony-stimulating factor approved by FDA, 411
- New method of analyzing health data stirs debate, 4
- New recommendations for prevention of bacterial endocarditis include amoxicillin use, 168
- News Briefs, 10, 94, 176, 253, 326, 417, 498, 573, 657, 739, 822, 898
- Ondansetron granted marketing approval, 249
- Recombinant granulocyte colony-stimulating factor approved by FDA, 321
- Report assesses use of blood pressure monitoring device for ambulatory patients, 175
- Report on pain management in childhood cancer published, 93
- Rubella prevention guidelines updated by CDC, 249
- Single large dose of intravenous immune globulin more effective than four-day regimen in patients with Kawasaki disease, investigators report, 657
- Study raises safety questions about β -agonist inhaler overuse, 822
- Study shows effect of postmenopausal estrogen therapy on cardiovascular risk, 897
- Study shows efficacy of monoclonal antibody in patients with sepsis and gram-negative bacteremia, 321
- Transdermal fentanyl approved for chronic pain management, 9
- Two cardiovascular agents, ramipril and isradipine, approved for U.S. market, 573
- Two reports on hypertension available from National Heart, Lung, and Blood Institute, 253
- Upcoming Specialty Meetings, 11, 94, 175, 326, 498, 574, 657, 739, 822, 898
- Year-end review shows 23 new drugs approved, 14
- Important biologic licensing actions taken by FDA, 167
- Niacin**; hyperlipidemia; therapy, protocols, 943
- Nicardipine**; proteinuria; therapy, diabetic nephropathies, 862
- Nicotinic acid**, see Niacin
- Nifedipine**; angina pectoris; unstable, therapy, 825
- Nitroglycerin**; angina pectoris; unstable, therapy, 825
- Nomograms**; warfarin; dosage, predictions, vs. computers, 923
- Nutrition**; parenteral; albumin human, dosage predictions, pediatrics, 704

O

- Ofloxacin**; effects; amikacin-resistant isolates, in vitro, 544
- Ondansetron hydrochloride**
- approvals; prophylaxis, chemotherapy toxicity, 249
- pharmacology; review, 430
- use; review, criteria, quality assurance programs, 471
- Opiates**

delirium; therapy, intensive-care units, 456
 pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667

Osteoarthritis
 etodolac; therapy, FDA approvals, 416
 therapy; geriatrics, ulcer history, 740

P

Pain
 analgesics; postoperative, continuous epidural infusions, 745
 fentanyl; transdermal patches, therapy, FDA approvals, 9
 ketorolac tromethamine; therapy, DUE criteria, 715
 therapy; acute, pediatrics, 667

Pancreatitis; pentamidine; toxicity, AIDS, hemophilia, 56

Panic disorders; therapy, 893

Paralysis; skeletal muscle relaxants; mechanically ventilated patients, 32

Parasympatholytic agents; asthma; therapy, pediatrics, 685

Parasympathomimetic agents; Alzheimer's disease; therapy, mechanism of action, review, 447

Parenterals, see **Injections**

Patches transdermal; fentanyl; pain therapy, FDA approvals, 9

Patient education; hypertension; ambulatory care, monitoring, devices, 175

Patients
 inpatients; gastrointestinal drugs, DUE criteria, 787;
 moricizine, DUE criteria, 873
 latex; medical devices, allergies, FDA recommendations, 417
 outpatients; fluconazole, DUE criteria, 222; ketorolac, DUE criteria, 715; moricizine, DUE criteria, 873;
 ondansetron therapy, DUE criteria, 471

Pediatrics
 albumin human; dosage predictions, parenteral supplements, 704
 analgesics; pain therapy, 667
 asthma; therapy, 685
 chloral hydrate; interactions, furosemide, 385
 fluconazole; DUE criteria, 222
 furosemide; interactions, chloral hydrate, 385
 ketorolac tromethamine; DUE criteria, 715
 labetalol hydrochloride; hypertension therapy, 500
 lactation; drugs, excretion, review, 594
 lorazepam; dosage, sedation, amnesia, 625
 mercury; poisoning, 213
 neonates; pulmonary surfactants, therapeutic equivalency, 909
 ondansetron hydrochloride; therapy, DUE criteria, 471
 phenytoin; dosage calculations, black African and Indian children, 928
 succimer; therapy, FDA approvals, 942
 vancomycin; neonates, dosage guidelines, 129

Penicillamine; hepatolenticular degeneration; therapy, 839

Pentamidine; toxicity; pancreatitis, AIDS, hemophilia, 56

Pentamidine isethionate; adverse reactions; facial numbness, infusions, 257

Pharmacists
 antiarrhythmic agents; therapy, blood levels, monitoring, 211
 arrhythmia; ventricular, therapy, monitoring, 210

Pharmacodynamics; glyburide; effects, age, 532

Pharmacogenetics
 phenytoin; dosage calculations, pediatrics, 928
 psychotherapeutic agents; race, ethnic groups, 467

Pharmacokinetics
 alfentanil; review, 581
 aminoglycosides; AIDS, 784
 analgesics; continuous epidural infusions, postoperative pain, 745; pain therapy, pediatrics, 667
 benazepril hydrochloride, 739
 doxazosin mesylate; hypertension therapy, 9
 drugs; lactation, excretion, review, 594
 etodolac, 416
 fentanyl; and derivatives, review, 581; transdermal patches, pain therapy, 9
 filgrastim, 321
 fluconazole; review, 179
 fludarabine phosphate, 496
 gallium nitrate, 573
 gentamicin; dosage predictions, methodology, 706
 glyburide; effects, age, 532
 ibuprofen; interactions, misoprostol, ranitidine, lack, 870

interleukin 2; review, 110
 isradipine, 573
 levamisole; review, 95
 lithium carbonate; methodology, models, 376
 ondansetron hydrochloride, 249; review, 430
 phenytoin; dosage calculations, pediatrics, 928
 phenytoin sodium; impaired metabolism, excretion, liver diseases, 711
 psychotherapeutic agents; race, ethnic groups, 467
 ramipril, 573
 recainam hydrochloride; computer programs, MS-DOS vs. Macintosh, 206
 sargramostim, 411
 skeletal muscle relaxants; review, mechanically ventilated patients, 32
 succimer; lead poisoning, therapy, 914
 sufentanil; review, 581
 triazolam; interactions, ranitidine, 539
 valproate sodium; syrups, availability, vs. valproic acid emulsions, 382
 valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
 vancomycin hydrochloride; relation, creatinine clearance, 297

Pharmacy, institutional, hospital
 quality assurance; programs, alfentanil, fentanyl, sufentanil, DUE criteria, 635; programs, enalapril, DUE criteria, 63; programs, erythropoietin, DUE criteria, 143, 303; programs, filgrastim, neutropenia prophylaxis DUE criteria, 950; programs, fluconazole, DUE criteria, 222; programs, heparin, DUE criteria, 549; programs, ketorolac, DUE criteria, 715; programs, midazolam, DUE criteria, 388; programs, misoprostol, DUE criteria, 307; programs, moricizine, arrhythmia therapy, DUE criteria, 873; programs, ondansetron, DUE criteria, 471; programs, sargramostim, DUE criteria, 947; programs, stress ulcer prophylaxis, DUE criteria, 787

Phenobarbital; epilepsy; therapy, review, 335

Phenytoin
 blood levels; effects, ultrafiltration and freezing, 132
 dosage; calculations, black African and Indian children, 928
 epilepsy; therapy, review, 335

Phenytoin sodium; excretion; impaired, liver diseases, activated charcoal therapy, 711

Phlebitis; injections; i.v. infusion sites, toxicity, 630

Physostigmine; Alzheimer's disease; therapy, mechanism of action, review, 447

Pituitary hormones; desmopressin acetate; high dose, mechanism of action, antidiuretic effects, 912

Platelet aggregation inhibitors
 aspirin; alone and with flurbiprofen, effects, 935
 flurbiprofen; alone and with aspirin, effects, 935

Pneumonia
 ceftazidime, comparison, ciprofloxacin lactate; nosocomial, therapy, 49
 ciprofloxacin lactate, comparison, ceftazidime; nosocomial, therapy, 49

Poisoning
 acetaminophen; overdose, acetylcysteine therapy, 765
 lead; succimer therapy, 914; succimer therapy, FDA approvals, controversies, 942
 mercury; dimercaprol, N-acetyl-DL-penicillamine, antidotes, pediatrics, 213; toxicity, hyperthyroidism, 742

Prescriptions; anabolic agents; steroids, reclassification, controlled substances, 417

Primidone; epilepsy; therapy, review, 335

Product withdrawal
 drugs, nonprescription; ingredients, FDA list, 88
 encainide hydrochloride; toxicity, 897

Propoxyphene; and aspirin; pain therapy, codeine allergies, 658

Propylthiouracil; hyperthyroidism; therapy, mercury poisoning, 742

Proteinuria; calcium antagonists; therapy, diabetic nephropathies, 862

Prothrombin time
 ciprofloxacin hydrochloride; interactions, warfarin, lack, 136
 warfarin; interactions, ciprofloxacin, lack, 136

Protocols
 alfentanil hydrochloride; DUE criteria, 635
 algorithms; ventricular arrhythmia therapy, 195
 enalapril maleate; DUE criteria, 63
 epoetin; DUE criteria, 143, 303
 fentanyl citrate; DUE criteria, 635
 filgrastim; neutropenia prophylaxis, chemotherapy, DUE criteria, 950
 fluconazole; DUE criteria, 222
 gastrointestinal drugs; stress ulcer prophylaxis, DUE criteria, 787
 heparin; thromboembolism therapy, 503

hetastarch; DUE criteria, 549
 hyperlipidemia; therapy, National Cholesterol Education Program, 943
 ketorolac tromethamine; DUE criteria, 715
 midazolam hydrochloride; DUE criteria, 388
 misoprostol; DUE criteria, 307
 moricizine; arrhythmia therapy, DUE criteria, 873
 ondansetron hydrochloride; DUE criteria, 471
 sargramostim; DUE criteria, 947
 sufentanil citrate; DUE criteria, 635
 vancomycin; dosage, neonates, 129
 warfarin; thromboembolism therapy, 503

Psychotherapeutic agents
 haloperidol; delirium therapy, intensive-care units, 456
 pharmacokinetics; race, ethnic groups, 467

Pulmonary surfactants
 alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; vs. beractant, therapeutic equivalency, 909
 beractant; vs. cetyl alcohol-colfosceril-tyloxapol, therapeutic equivalency, 909

Q

Quality assurance
 hospital pharmacy; programs, alfentanil, fentanyl, sufentanil, DUE criteria, 635; programs, enalapril, DUE criteria, 63; programs, epoetin, DUE criteria, 143, 303; programs, filgrastim, neutropenia prophylaxis, DUE criteria, 950; programs, fluconazole, DUE criteria, 222; programs, heparin, DUE criteria, 549; programs, ketorolac, DUE criteria, 715; programs, midazolam, DUE criteria, 388; programs, misoprostol, DUE criteria, 307; programs, moricizine, arrhythmia therapy, DUE criteria, 873; programs, ondansetron, DUE criteria, 471; programs, sargramostim, DUE criteria, 947; programs, stress ulcer prophylaxis, DUE criteria, 787

Quality of life; thionazine hydrochloride; generic equivalency, brands, comparison, 938

Quinidine; concomitant therapy, 823

Quinolones
 ciprofloxacin; susceptibility, amikacin-resistant isolates, in vitro, 544
 ciprofloxacin hydrochloride; interactions, warfarin, PT effects, lack, 136
 ciprofloxacin lactate; vs. ceftazidime, pneumonia and urinary tract infections therapy, 49
 Mycobacterium avium complex; therapy, AIDS, review, 280
 ofloxacin; susceptibility, amikacin-resistant isolates, in vitro, 544

R

Race
 patients; psychotherapeutic agents, pharmacogenetics, 467
 pediatrics; phenytoin dosage calculations, 928

Radionuclides; neoplasms; monoclonal antibodies, 359

Radiopharmaceuticals; neoplasms; monoclonal antibodies, 359

Ramipril; marketing; FDA approvals, 573

Ranitidine; ulcers; peptic, prophylaxis, osteoarthritis therapy, geriatrics, 740

Ranitidine hydrochloride; interactions; ibuprofen, lack, 870; triazolam, pharmacokinetics, 539

Rational therapy
 cardiac drugs; ventricular arrhythmia therapy, 195
 pharmacists; ventricular arrhythmia, monitoring, 210

Recainam hydrochloride; pharmacokinetics; computer programs, MS-DOS vs. Macintosh, 206

Reference books; lactation; drugs, patient information, review, 594

Regulations
 Food and Drug Administration; nonprescription ingredients, withdrawal, 88
 succimer; therapy, FDA restrictions, 942

Replacement solutions; hetastarch; DUE criteria, quality assurance programs, 549

Reports
 botulinum toxin type A; dystonia therapy, 88
 drugs, adverse reactions; and toxicity, Vaccine Adverse Event Reporting System, 9
 hypertension; monitoring, devices, assessment, 175

Research
 acquired immunodeficiency syndrome; therapy, AIDS conference, 809
 hypertension; monitoring, devices, assessment, 175

Resistance
 amikacin; gram-negative bacteria, in vitro, 544

ceftazidime, comparison, ciprofloxacin lactate; pneumonia and urinary tract infections, 49
 ciprofloxacin lactate, comparison, ceftazidime; pneumonia and urinary tract infections, 49
Respiratory distress syndrome; pulmonary surfactants; therapy, therapeutic equivalency, 909
Respiratory smooth-muscle relaxants; theophylline; asthma therapy, 685
Restless legs; therapy; nocturnal, 427
Rhenium Re 188; radionuclides; monoclonal antibodies, neoplasms, 359
RS-86; Alzheimer's disease; therapy, mechanism of action, review, 447

S

Salsalate; osteoarthritis; therapy, geriatrics, ulcer history, 740
Sargramostim
 marketing; FDA approvals, 411
 use; evaluation, criteria, 947
Scleroderma; therapy; systemic, 14
Sex; patients; males, toxicity, i.v. infusion sites, 630
Skeletal muscle relaxants
 delirium; therapy, intensive-care units, 456
 pharmacology; review, mechanically ventilated patients, 32
 therapy; nocturnal leg cramps, restless legs, 427
Sorbitol; vehicles; activated charcoal therapy, phenytoin toxicity, liver diseases, 711
Stability
 ondansetron hydrochloride; review, 430
 phenytoin; blood levels, freezing, ultrafiltration, 132
 valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
Staphylococcus aureus; resistance; ciprofloxacin, pneumonia, 49
Steroids; anabolic agents; reclassification, controlled substances, 417
Steroids, cortico-; asthma; therapy, 685
Storage; effects; phenytoin blood levels, ultrafiltration methods, 132
Streptococcus species; resistance; ciprofloxacin, pneumonia, 49
Streptokinase; comparison, alteplase, anistreplase; myocardial infarction therapy, 486
Succimer
 marketing; FDA approvals, controversies, 942
 therapy; lead poisoning, 914
Sucralfate; use; evaluation, stress ulcer prophylaxis, criteria, 787
Sufentanil pharmacology; clinical uses, review, 581
Sufentanil citrate; use; review, criteria, quality assurance programs, 635
Surgical supplies; latex; adverse reactions, FDA recommendations, 417
Sympatholytic agents
 β blockers; and doxazosin, hypertension therapy, 9
 scleroderma; systemic, therapy, 14
Sympathomimetic agents
 asthma; therapy, 685
 heart failure; congestive, therapy, diastolic dysfunction, 850
Syrups; valproate sodium; stability, availability, vs. valproic acid emulsions, 382

T

Tacrine hydrochloride; Alzheimer's disease; therapy, mechanism of action, review, 447
Taste; palatability; cholestyramine, colestipol, oral formulations, 138
Terbutaline sulfate; labor; preterm, home infusion therapy, 292
Tests, laboratory
 phenytoin; blood levels, effects, ultrafiltration and freezing, 132
 prothrombin; warfarin, interactions, ciprofloxacin, lack, 136
Theophylline; asthma; therapy, 685
Therapy Consultation, 12, 427, 658, 740, 909
 Analgesic selection when the patient is allergic to codeine, 658
 Comparing surfactant products, 909
 Treatment of nocturnal leg cramps and restless leg syndrome, 427
 Treatment options for a patient with osteoarthritis and a history of ulcer disease, 740
 Use of ketoconazole in the treatment of Cushing's syndrome, 12
Thioridazine hydrochloride; equivalency, generic;

brands, comparison, efficacy, quality of life, 938
Thromboembolism
 heparin; therapy, guidelines, 503
 warfarin; therapy, guidelines, 503
Thrombolytic agents; myocardial infarction; therapy, 486
Tissue levels; mercury; poisoning, pediatrics, 213
Tissue plasminogen activator, see **Alteplase**
Tocolytics; terbutaline sulfate; preterm labor, home infusion therapy, 292
Toxicity, environmental
 mercury; poisoning, occupational exposure, hyperthyroidism, 742; spills, inhalation, poisoning, pediatrics, 213
 meta-analysis; methodology, applications and problems, 4
Toxicity
 see also **Drugs, adverse reactions**
 acetaminophen; overdose, acetylcysteine therapy, 765
 allentani hydrochloride; DUE criteria, 635
 analgesics; side effects, continuous epidural infusions, 745; side effects, pain therapy, pediatrics, 667
 anti-inflammatory agents; osteoarthritis therapy, geriatrics, ulcer history, 740
 antineoplastic agents; nausea and vomiting, ondansetron prophylaxis, 430; neutropenia, filgrastim prophylaxis, FDA approvals, 321; ondansetron prophylaxis, FDA approvals, 249
 benazepril hydrochloride, 739
 botulinum toxin type A; side effects, 88
 cardiac drugs; ventricular arrhythmia therapy, 195
 chloral hydrate; interactions, furosemide, pediatrics, 385
 deferoxamine mesylate; side effects, hemochromatosis therapy, 775
 digoxin; therapy, digoxin immune Fab retreatment, immunogenicity, 823
 doxazosin mesylate; side effects, hypertension therapy, 9
 drugs; lactation, 594
 enalapril maleate; DUE criteria, 63
 encainide hydrochloride; side effects, product withdrawal, 897
 epoetin; DUE criteria, 143, 303
 etodolac; side effects, 416
 fentanyl; side effects, transdermal patches, pain therapy, 9
 fentanyl citrate; DUE criteria, 635
 filgrastim; neutropenia prophylaxis, DUE criteria, 950; side effects, 321
 fluconazole; DUE criteria, 222; side effects, review, 179
 fludarabine phosphate; side effects, 496
 furosemide; interactions, chloral hydrate, pediatrics, 385
 gallium nitrate; side effects, 573
 gastrointestinal drugs; stress ulcer prophylaxis, DUE criteria, 787
 hetastarch; DUE criteria, 549
 injections; i.v. infusion, extravasation, phlebitis, 630
 interleukin 2; side effects, neoplasms therapy, 110
 isradipine; side effects, 573
 ketorolac tromethamine; DUE criteria, 715
 labetalol hydrochloride; side effects, lack, pediatrics, 500
 lead; poisoning, succimer therapy, 914
 levamisole; side effects, colorectal neoplasms therapy, 95
 lorazepam; side effects, high dose, pediatrics, 625
 mercury; hyperthyroidism, long-term exposure, 742; poisoning, pediatrics, 213
 midazolam hydrochloride; DUE criteria, 388
 misoprostol; DUE criteria, 307
 moricizine; arrhythmia therapy, DUE criteria, 873
 ondansetron hydrochloride; DUE criteria, 471; side effects, 249; side effects, review, 430
 pentamidine; pancreatitis, AIDS, hemophilia, 56
 phenytoin sodium; impaired metabolism, liver diseases, 711
 ramipril; side effects, 573
 sargramostim; DUE criteria, 947; side effects, 411
 skeletal muscle relaxants; side effects, mechanically ventilated patients, 32
 succimer; side effects, lead poisoning therapy, 914
 sufentanil citrate; DUE criteria, 635
 terbutaline sulfate; side effects, preterm labor therapy, 292
 thrombolytic agents; side effects, myocardial infarction therapy, 486
 vaccines; side effects, Vaccine Adverse Event Reporting System, 9
 zidovudine; neutropenia, HIV infections, review, 268
Toxins; botulinum toxin type A; dystonia therapy, 88
t-PA, see **Alteplase**

Tranquilizers; thioridazine hydrochloride; generic equivalency, comparisons, efficacy, quality of life, 938
Transplantation; bone marrow; acute lymphoblastic leukemia patients, sargramostim therapy, FDA approvals, 411; sargramostim therapy, DUE criteria, 947
Triazolam; interactions; ranitidine, pharmacokinetics, 539
Trientine; hepatolenticular degeneration; therapy, 839
Tyloxapal; combination, alcohols, cetyl, colfosceril palmitate; vs. beractant, therapeutic equivalency, 909

U

Ulcers
 gastrointestinal drugs; stress, prophylaxis, DUE criteria, 787
 misoprostol; gastric, therapy, DUE criteria, 307
 prophylaxis; peptic, osteoarthritis, geriatrics, 740
Urinary tract infections
 ceftazidime, comparison, ciprofloxacin lactate; therapy, 49
 ciprofloxacin lactate, comparison, ceftazidime; therapy, 49
Urine levels; mercury; poisoning, pediatrics, 213

V

Vaccine Adverse Event Reporting System; vaccines; adverse reactions and toxicity, reports, 9
Vaccines; toxicity; and adverse reactions, Vaccine Adverse Event Reporting System, 9
Valproate sodium; comparison, valproic acid; stability, availability, emulsions vs. syrups, 382
Valproic acid
 comparison, valproate sodium; stability, availability, emulsions vs. syrups, 382
 epilepsy; therapy, review, 335
Vancomycin; dosage; guidelines, neonates, 129
Vancomycin hydrochloride; blood levels; half-life, relation creatinine, hepatic and renal dysfunction, 297
Vasodilating agents; heart failure; congestive, therapy, diastolic dysfunction, 850
Vehicles
 cholestyramine resin; palatability, oral formulations, preferences, 138
 colestipol hydrochloride; palatability, oral formulations, preferences, 138
 sorbitol; activated charcoal therapy, phenytoin toxicity, liver diseases, 711
Ventilators; skeletal muscle relaxants; mechanical, patients, effects, 32
Verapamil
 angina pectoris; unstable, therapy, 825
 muscle cramp; therapy, nocturnal leg cramps, 427
Vitamin E; muscle cramp; therapy, nocturnal leg cramps, 427
Volume of distribution, see **Drugs, body distribution**
Vomiting; ondansetron hydrochloride; therapy, DUE criteria, 471

W

Warfarin
 interactions; ciprofloxacin, PT effects, lack, 136
 nomograms; dosage, predictions, vs. computers, 923
 thromboembolism; therapy, guidelines, 503
Weight; patients; predictions, lithium clearance, models, 376

X

Xanthomonas maltophilia; resistance; antibiotics, in vitro, 544

Y

Yttrium Y 90; radionuclides; monoclonal antibodies, neoplasms, 359

Z

Zidovudine; toxicity; neutropenia, HIV infections, review, 268
Zinc; hepatolenticular degeneration; maintenance therapy, 839

Author Index

A

- Allen, Nancy M. Retreatment with digoxin immune Fab (letter), 823
 Altman, Lawrence K. New method of analyzing health data stirs debate (News), 4
 Anderson, Bruce D. see Smith, Leanne B., 132
 Anderson, Philip O. Drug use during breast-feeding, 594
 Antal, Edward J. see Schwinghammer, Terry L., 532
 Ariano, Robert E. Inverse relationship between desmopressin dosage and antidiuresis (letter), 912
 Asher, John P. Use of angiotensin-converting-enzyme inhibitors in the management of renal disease, 25

B

- Bablenis, Elena Effect of use of generic thioridazine products on clinical outcome and quality of life, 938
 Banner, William Jr. Succimer: controversial issues involving the release of a new product (editorial), 942
 Barnett, Michael D. see McGee, Barbara A., 14
 Basile, Sharon A. Criteria for use of hetastarch, 549
 Baumann, Terry J. Analgesic selection when the patient is allergic to codeine (Therapy Consultation), 658
 Beall, Barbara see Matsuyama, Joy R., 544
 Bennett, Teresa A. Criteria for use of epoetin, 143, 303
 Bennett, Teresa A. Criteria for use of moricizine in adult inpatients and outpatients, 873
 Berardi, Rosemary R. see Knapp, Margaret J., 866
 Bernard, Evelyn see Dellamonica, Pierre, 301
 Bhatt-Mehta, Varsha Management of acute pain in children, 667
 Billeter, Marianne see Rapp, Robert P., 49
 Bombard, Paul A. see Vanderveen, R. Pete, 539
 Bond, William S. Ethnicity and psychotropic drugs, 467
 Botha, Julia H. Estimating phenytoin dosages in black African and Indian children, 928
 Bourne, David W. A. see Hampton, Edward M., 206
 Bourne, Kimberly M. Criteria for use of fluconazole in adult and pediatric inpatients and outpatients, 222
 Buck, Marcia L. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients, 32
 Burwinkle, Joseph W. see Henry, David W., 625

C

- Calis, Karim Anton see Kintzel, P. E., 110
 Carles, Michel see Dellamonica, Pierre, 301
 Carter, Barry L. Therapy of acute thromboembolism with heparin and warfarin, 503
 Carver, Peggy L. see Knapp, Margaret J., 866
 Chae, Joanne S. see Nakahiro, Randall K., 931
 Chaffee, Betty J. Ondansetron—the first of a new class of antiemetic agents, 430
 Check, William A. Conference attendees told ISIS-3 shows equal efficacy, safety differences among thrombolytics (News), 486
 Chin, Alfred see Nakahiro, Randall K., 931
 Cloiz, Michael A. Clinical uses of fentanyl, sufentanil, and alfentanil, 581
 Cochran, Emily B. Prediction of serum albumin concentration after albumin supplementation in pediatric patients receiving parenteral nutrition, 704
 Coleman, Robert W. see Fredriks, Dean A., 923
 Coley, Allison L. Criteria for use of enalapril maleate in adults, 63
 Collins, Shelly Rainforth see Gabriel, Mariane Hardenbrook, 129
 Comstock, Thomas J. Book review, 890
 Connce, Shannon L. see Murphy, Christine M., 685
 Cortese, Linda M. Criteria for use of midazolam hydrochloride in adult patients, 388
 Couch, Patricia Cryoprecipitate for uremic bleeding (letter), 429
 Cox, Steven R. see Vanderveen, R. Pete, 539
 Crismon, M. Lynn see Jermain, Donna M., 376

D

- Davenport, Robertson Cryoprecipitate for uremic bleeding (letter), 429
 Davis, Lisa E. see Spinler, Sarah A., 825

- Dean, Roger P. Interaction of chloral hydrate and intravenous furosemide in a child, 385
 Dellamonica, Pierre Preventing recurrent varicella and herpes zoster with oral acyclovir in HIV-seropositive patients, 301
 Dempsey, Robert J. see Rapp, Robert P., 49
 Dixon, Dennis M. see Kowalsky, Steven F., 179
 Donnelly, Andrew J. see Shafer, Amy L., 745
 Dressman, Jennifer B. see Knapp, Margaret J., 866
 Dufresne, Robert L. see Bablenis, Elena, 938

E

- Eaton, Virginia E. see Rathbun, R. Chris, 280

F

- Fischer, Janet R. Continuous subcutaneous infusion of terbutaline for suppression of preterm labor, 292
 Fish, Douglas N. Treatment of delirium in the critically ill patient, 456
 Fish, Susan S. Book review, 730
 Florentine, Mauro J. Elemental mercury poisoning, 213
 Floridia, Donald G. Book review, 649
 Forrest, Alan see Weidle, Paul J., 711
 Fredriks, Dean A. Nomogram for dosing warfarin at steady state, 923

G

- Gabriel, Mariane Hardenbrook Prospective evaluation of a vancomycin dosage guideline for neonates, 129
 Garabedian-Ruffalo, Susan M. see Salties, Emmanuel, 518
 Garewal, Harinder S. see Rindone, Joseph P., 136
 Garnett, William R. see Pugh, Carol B., 335
 Gennrich, Jane L. see Gabriel, Mariane Hardenbrook, 129
 Gill, Mark A. see Nakahiro, Randall K., 931
 Gilman, Jamie T. Valproic acid hepatotoxicity in adults and older children (letter), 665
 Goodwin, S. Diane see Bourne, Kimberly M., 222
 Gora, Mary Lea Book review, 805
 Graves, David A. Book review, 970
 Green, Elaine R. Book review, 729

H

- Hackimer, Mary E. see Schwinghammer, Terry L., 532
 Hak, Lawrence J. see O'Neil, Michael G., 56
 Hampton, Edward M. Comparison of MS-DOS and Macintosh pharmacokinetic analysis programs using a two-compartment, two-infusion dosing scheme, 206
 Hartwig, Steven C. Criteria for use of ondansetron hydrochloride in adult and pediatric inpatients and adult outpatients, 471
 Hasegawa, Guy R. Antiarrhythmic monitoring: misplaced emphasis (editorial), 211
 Hatton, Jimmi see Rapp, Robert P., 49
 Hatton, Randy C. see Veerman, Mark W., 382
 Hecker, John see Wright, Alex, 630
 Henry, David W. Determination of sedative and amnestic doses of lorazepam in children, 625
 Hogue, Susan L. see Cochran, Emily B., 704
 Housel, Ben F. see Ishisaka, Denis Y., 500
 Hrdlicka, Kyle see Hampton, Edward M., 206
 Hutson, Paul R. see Mutch, Rebecca S., 95

I

- Ishisaka, Denis Y. Labetalol for treatment of hypertension in a child (letter), 500
 Israel, Deb S. Neutropenia in patients infected with human immunodeficiency virus, 268
 Ito, Matthew K. Acceptability of cholestyramine and colestipol formulations in three common vehicles, 138

J

- Jacobi, Judith Book review, 80

- Jermain, Donna M. Population pharmacokinetics of lithium, 376
 Jirak, Jana L. see Vanderveen, R. Pete, 539
 Johanson, Franck see Dellamonica, Pierre, 301
 Johnston, Juli A. Diastolic dysfunction in congestive heart failure, 850
 Johnston, Jann M. see Schwinghammer, Terry L., 532
 Jones, Paul R. see McMorrow, Julie, 501
 Jones, William N. see Rindone, Joseph P., 136

K

- Kaatz, Brian L. see Fischer, Janet R., 292
 Kelleher, Michael D. see Dean, Roger P., 385
 Keller, James H. Book review, 239
 Kelley, Catherine L. see Rindone, Joseph P., 136
 Khanderia, Ujjaini Use of ketoconazole in the treatment of Cushing's syndrome (Therapy Consultation), 12
 Kildoad, Carl W. III see Gabriel, Mariane Hardenbrook, 129
 Kintzel, P. E. Recombinant interleukin-2: a biological response modifier, 110
 Kirking, Marilyn H. Treatment of chronic iron overload, 775
 Klutman, Neil E. see Henry, David W., 625
 Knapp, Margaret J. Modification of gastric pH with oral glutamic acid hydrochloride, 866
 Knight, Matthew E. see Veerman, Mark W., 382
 Kolb, Kenneth W. see Walton, Ted, 427
 Kowalsky, Steven F. Fluconazole: a new antifungal agent, 179
 Kresel, James J. Book review, 243
 Kubacka, René T. see Schwinghammer, Terry L., 532

L

- Lackner, Thomas E. A nonexponential, nonlogarithmic, pharmacokinetic dosing method for gentamicin, 706
 Lewis, Richard K. Assessment and treatment of acetaminophen overdose, 765
 Lin, Anne Y. F. Pentamidine-induced facial numbness (letter), 257
 Lokic, François see Dellamonica, Pierre, 301
 Longley, Joyce M. Altered aminoglycoside volume of distribution in patients with acquired immunodeficiency syndrome, 784
 Lopez, Larry M. Verapamil and left ventricular hypertrophy (letter), 333

M

- Mann, Katherine V. Succimer, an oral lead chelator, 914
 Martin, Emory S. III see Jermain, Donna M., 376
 Martin, Emory S. III see also Rathbun, R. Chris, 280
 Matsuyama, Joy R. Book review, 976
 Matsuyama, Joy R. Susceptibility of *Xanthomonas maltophilia* and amikacin-resistant gram-negative bacteria to newer antimicrobials, 544
 Matthew, Earl B. see Rathbun, R. Chris, 280
 May, J. Russell Book review, 885
 McCann, Michael Hyperthyroidism associated with mercury poisoning (letter), 742
 McCollam, Patrick L. Evaluation and treatment of ventricular arrhythmias: an update, 195
 McGee, Barbara A. Current options for the treatment of systemic scleroderma, 14
 McGee, Barbara A. see also Small, Ralph E., 870
 McMorrow, Julie Antimicrobial dosages in guidelines for prevention of bacterial endocarditis, 501
 Medina, Richard A. see Peters, Mark D. II, 787
 Mendel, Stephen Book review, 805
 Michael, Katherine A. see Peters, Mark D. II, 787
 Miller, Alan B. see Bennett, Teresa A., 873
 Miller, Donald R. Treatment options for a patient with osteoarthritis and a history of ulcer disease (Therapy Consultation), 740
 Miller, Raymond see Botha, Julia H., 928
 Modanlou, Houchang D. see Gabriel, Mariane Hardenbrook, 129
 Mondain, Véronique see Dellamonica, Pierre, 301
 Moodley, Manikum see Botha, Julia H., 928
 Morrales, Anthony P. see Ito, Matthew K., 138
 Murphy, Christine M. Treatment of asthma in children, 685

- Murray, Kim M. Calcium-channel blockers for treatment of diabetic nephropathy, 862
Murray, Kim M. see also Asher, John P., 25
Mutch, Rebecca S. Levamisole in the adjuvant treatment of colon cancer, 95

N

- Nahata, Milap C. see Clotz, Michael A., 581
Nahata, Milap C. see also McMorrow, Julie, 501
Nakahiro, Randall K. Use of gentamicin clearance in estimating renal function, 931
Nappi, Jean Trials and tribulations of evaluating ventricular arrhythmias (editorial), 210
Newby, F. David see Longley, Joyce M., 784

O

- O'Neill, Michael G. Pancreatitis during pentamidine therapy in patients with AIDS, 56
Okamoto, Mark P. see Nakahiro, Randall K., 931
Orlando, Patricia L. Book review, 885

P

- Pachorek, Robert E. Vancomycin half-life in a patient with hepatic and renal dysfunction, 297
Paloucek, Frank P. see Lewis, Richard K., 765
Parish, Roy C. see Pincus, Kelly T., 935
Parker, Robert B. see McCollam, Patrick L., 195
Peloquin, Charles A. Dosage of antimycobacterial agents (letter), 664
Peters, Gary R. see Vanderveen, R. Pete, 539
Peters, Mark D. II Criteria for stress ulcer prophylaxis in intensive-care patients, 787
Pincus, Kelly T. Effect of flurbiprofen and aspirin on platelet aggregation, 935
Pittman, Donald G. see Longley, Joyce M., 784
Plaisance, Karen I. see Israel, Deb S., 268
Porter, Don R. Book review, 316
Prevost, Rebecca Rogers Comparing surfactant products (Therapy Consultation), 909
Price, Karen Overstreet Ethnicity and clozapine-induced agranulocytosis (letter), 743
Pugh, Carol B. Current issues in the treatment of epilepsy, 335
Pugh, Carol B. see also Smith, Leanne B., 132

R

- Rapp, Robert P. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection, 49
Rathbun, R. Chris Current and investigational therapies for AIDS-associated *Mycobacterium avium* com-

plex disease, 280

- Reed, Michael D. see Buck, Marcia L., 32
Reilly, Raymond M. Radioimmunotherapy of malignancies, 359
Rider, Joan M. see Knapp, Margaret J., 866
Rindone, Joseph P. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin, 136
Rosen, David A. see Bhatt-Mehta, Varsha, 667
Rudinsky, Brian F. see Dean, Roger P., 385
Rutledge, David R. Which lipid-lowering agent should be used first? 943

S

- Saltiel, Emmanuel Pharmacologic management of endometriosis, 518
Sandroni, Stephen see Bennett, Teresa A., 143, 303
Sanfilippo, Dominic J. II see Florentine, Mauro J., 213
Satterlee, Grant B. Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride, 635
Scheckner, Stuart see McCann, Michael, 742
Scholten, Stephanie L. Correction to *AHFS Drug Information* 91 (letter), 913
Schwinghammer, Terry L. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults, 532
Sclar, David A. see Nakahiro, Randall K., 931
Selub, Steven E. see O'Neill, Michael G., 56
Seymour, Beverly see Ariano, Robert E., 912
Shafer, Amy L. Management of postoperative pain by continuous epidural infusion of analgesics, 745
Shepherd, Michele F. Criteria for use of ketorolac tromethamine in adult inpatients and outpatients, 715
Simon, Pamela A. see Murphy, Christine M., 685
Sjolander, Julie A. see Peters, Mark D. II, 787
Skies, Daniel J. see Weidle, Paul J., 711
Skora, Irene A. see Satterlee, Grant B., 635
Small, Ralph E. Effects of misoprostol or ranitidine on ibuprofen pharmacokinetics, 870
Small, Ralph E. see also McGee, Barbara A., 14
Smith, Candace see Lin, Anne Y. F., 257
Smith, Leanne B. Effect of ultrafiltration product and ultrafiltration-freezing sequence on free phenytoin determination, 132
Spinler, Sarah A. Advances in the treatment of unstable angina pectoris, 825
Spruill, William J. see Pincus, Kelly T., 935
Stahl-Bayliss, Celine M. Interferon for genital warts (letter), 177
Swanson, Keith A. see Peters, Mark D. II, 787

T

- Tami, Joseph A. Recombinant interleukin-2 and the quest for FDA approval, 141
Tankanow, Roberta M. Pathophysiology and treatment of Wilson's disease, 839
Tankanow, Roberta M. see also Chaffee, Betty J., 430
Tartaglione, Teresa see Matsuyama, Joy R., 544
Thom, Claire M. Verapamil and left ventricular hy-

per trophy (letter), 333

- Tibbs, Phillip A. see Rapp, Robert P., 49
Todd, Mark W. Criteria for use of misoprostol, 307
Todd, Mark W. see also Bennett, Teresa A., 143, 303
Travers, John D. see Mann, Katherine V., 914
Trotter, J. Mark see Bennett, Teresa A., 873

U

- Uden, Don Book review, 650

V

- Vanderveen, R. Pete Effect of ranitidine on the disposition of orally and intravenously administered triazolam, 539
Veerman, Mark W. Relative bioavailability and stability of extemporaneously prepared valproic acid emulsion, 382
Volger, Burgunda W. Alternatives in the treatment of memory loss in patients with Alzheimer's disease, 447
Volger, Burgunda W. Book review, 317

W

- Wallis, Carolyn see Matsuyama, Joy R., 544
Walton, Ted Treatment of nocturnal leg cramps and restless leg syndrome (Therapy Consultation), 427
Weber, Stanley S. see Bablenis, Elena, 938
Weidle, Paul J. Multiple-dose activated charcoal as adjunct therapy after chronic phenytoin intoxication, 711
Weiss, Peter D. see Lackner, Thomas E., 706
Welty, Timothy E. Book review, 159
Willis, Hayes E. see Small, Ralph E., 870
Willmot-Pater, Melody G. see Small, Ralph E., 870
Wittkowski, Ann K. Laboratory monitoring of heparin therapy (letter), 824
Wong, Roberta J. Highlights of the Seventh International Conference on AIDS (News), 809
Wood, Frederick see Pachorek, Robert E., 297
Wright, Alex Infusion failure caused by phlebitis and extravasation, 630

Y

- Yamreudeewong, Weeranuj see Lackner, Thomas E., 706
Yonan, Charles D. see Ishisaka, Denis Y., 500
Young, A. Bryon see Rapp, Robert P., 49

Z

- Zeleznik, Dee see Matsuyama, Joy R., 544

Advertising Index

A

- Adria Laboratories**
Idamycin, 5-7, Feb 160, IBC, OBC, Apr 318, IBC, OBC, Jun 482, IBC, OBC
- American Diabetes Association**
Institutional, 13, 739
- American Lung Association**
Institutional, 326
- American Society of Hospital Pharmacists**
AHFS Drug Information 91, 239, 334, 554
AHFS Drug Information 92, 978
American Journal of Hospital Pharmacy, 629
Aseptic Preparation of Parenteral Products, 67, 238
ASHP Membership, 212, 783, 979
CiteSearch, 256, 416
Clinical Pharmacy, 159, 221, 291, 401, 428, 738
Concepts in Clinical Pharmacokinetics, 317, 741, 969
Concepts in Immunology and Immunotherapeutics, 13, 400, 420
Criteria for Drug Use Evaluation, Volumes 1 and 2, Jan IFC, 261, 391, 476, 499, 640, 666, 952
European Drug Index, 315, 403, 559, 580
Guidelines for Administration of Intravenous Medications to Pediatric Patients, 548, 990
Handbook on Injectable Drugs, 6th Edition, 232, 302
International Pharmaceutical Abstracts, 231, 358
IV-EASE, 150
Medication Errors: A Closer Look, 744
Medication Teaching Manual, Fourth Edition, 178, 266
MedTeach, 531, 806
Pocket Guide to Injectable Drugs, 1991 Edition, 70, 236, 470, 574
Position Available, 744
QARx, 404, 725
Rx Triage, 267, 387
Safe Handling of Cytotoxic and Hazardous Drugs, 94, 253, 945
Software, 967
- Amgen Inc.**
Epogen, Sep IFC, Oct IFC, 961-965
Neupogen, 899-908
- ASHP Research and Education Foundation**
Anticoagulation Clinic Traineeship Program, 557
Awards Program, 75
Institutional, 89, 977

B

- Baxter Healthcare Corporation, Hyland Division**
Gammagard, 412-414, 488-490
- Burroughs Wellcome Company**
Exosurf Neonatal, 491-495, 575-579, 659-663, 795-799, 815-819, 971-975
Zovirax I.V., 76-78, 90-92, 240-242, 258-260, 322-324, 408-410, 560-562, 646-648

C

- Charleston Area Medical Center**
Position Available, 150

D

- Department of Veterans Affairs (Richmond)**
Positions Available, 73, 83, 163, 265, 325, 415, 563

E

- Eisenhower Medical Center**
Positions Available, 237, 416, 954

G

- Glaxo Inc.**
Antiemetic, Feb IFC
Ceptaz, 244-246, 254-256, 398-400
Zofran, 169-174, 327-332, 421-426

H

- Harrisburg Hospital**
Position Available, 11

I

- International Pharmaceutical Federation (F.I.P.)**
Membership, 643

K

- Kent General Hospital**
Position Available, 94

L

- Eli Lilly and Company**
Hospital Division, 3, 153, Mar IFC, Jun IFC, 485, 813
- Lyphomed, Inc.**
Amphotericin B, 84-86, 164-166, 262-264

M

- Methodist Medical Center of Illinois**
Position Available, 497

N

- National Easter Seal Society**
Institutional, 879
- National Foundation for Infectious Diseases**
National Forum, 910

P

- The Pharmacy Council on Cholesterol**
10 Cholesterol Battle Strategies, 502

R

- Roche Laboratories, Division of Hoffmann-La Roche, Inc.**
Rocephin, Aug IBC, OBC, Oct IBC, OBC, Dec IBC, OBC
- Roerig, A Division of Pfizer Pharmaceuticals**
Diffucan, 156-158, 250-252, May IFC, 407, Jul IFC, Aug IFC, 719-722
Unasyn, 418-420
- Ross Laboratories**
Survanta, 737-738, 883-884

S

- San Francisco VA Medical Center**
Position Available, 13
- Schering-Plough Corporation**
Position Available, 497
- SmithKline Beecham**
Tagamet, Jan IBC, OBC, Mar IBC, OBC, May IBC, OBC, Jul IBC, OBC, Sep IBC, OBC, Nov IBC, OBC
- St. Jude Children's Research Hospital**
Institutional, 11, 310, 665

T

- Toledo Hospital**
Positions Available, 649, 913

U

- The University Hospital (Boston)**
Position Available, 334
- The University of Illinois College of Medicine at Peoria**
Positions available, 499
- The University of Rhode Island**
Position Available, 11
- The Upjohn Company**
Zefazone, 810-812, 956-958
- The Upjohn Company and Chugai-Upjohn, Inc.**
Marogen 79, 87, Apr IFC

W

- Wyeth-Ayerst Laboratories, Inc.**
Ativan Injection, 564-566, 570-572, 654-656, 734-736, 886-888, 894-896
Position Available, 176
Tubex, Nov IFC, Dec IFC